| P50 | author | Domenico Plantone | Q56944467 |
| | Tatiana Koudriavtseva | Q59661369 |
| P2093 | author name string | Tatiana Koudriavtseva | |
| P2860 | cites work | Microbial translocation is a cause of systemic immune activation in chronic HIV infection | Q22251054 |
| | Drugs for discoid lupus erythematosus | Q24240456 |
| | Chikungunya virus infection | Q24497757 |
| | Q fever | Q24550722 |
| | Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network | Q26799713 |
| | Chloroquine and hydroxychloroquine for cancer therapy | Q26827797 |
| | Cardiac toxicity secondary to long term treatment with chloroquine | Q28360029 |
| | Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness | Q28367732 |
| | Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation | Q28379104 |
| | Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis | Q28545984 |
| | Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen | Q28599242 |
| | Baseline Prevalence of Birth Defects Associated with Congenital Zika Virus Infection — Massachusetts, North Carolina, and Atlanta, Georgia, 2013–2014 | Q28956693 |
| | Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 |
| | Assessing real-time Zika risk in the United States | Q30145655 |
| | Drugs for discoid lupus erythematosus. | Q30234556 |
| | Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. | Q30359528 |
| | The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study | Q30885847 |
| | The anti-HIV-1 activity of chloroquine | Q31884593 |
| | Factors associated with low bone mineral density in female patients with systemic lupus erythematosus | Q31984501 |
| | Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis | Q33326642 |
| | Hydroxychloroquine in lupus pregnancy | Q33373145 |
| | Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis | Q33667694 |
| | Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 |
| | Effects of chloroquine on viral infections: an old drug against today's diseases? | Q33973620 |
| | Antimalarial agents: closing the gate on Toll-like receptors? | Q79158393 |
| | Neurosarcoidosis | Q80184825 |
| | Ocular toxicity of hydroxychloroquine | Q81141186 |
| | Porphyria cutanea tarda: treatment options revisited | Q84976648 |
| | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment | Q86328050 |
| | Whipple's disease | Q88008833 |
| | Sjögren's syndrome | Q88701707 |
| | New concepts in antimalarial use and mode of action in dermatology | Q34007922 |
| | Chloroquine and the fungal phagosome | Q34022942 |
| | Chloroquine-resistant malaria | Q34087800 |
| | Clinical relapse in Whipple's disease despite maintenance therapy | Q34098579 |
| | Hydroxychloroquine neuromyotoxicity | Q34112561 |
| | Antimalarials. | Q34129797 |
| | Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy | Q34158360 |
| | Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy | Q34162386 |
| | Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens | Q34226242 |
| | Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis | Q34259032 |
| | From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy | Q34260800 |
| | Antimalarials--the 'real' advance in lupus | Q34297582 |
| | Chloroquine cardiomyopathy - a review of the literature | Q34342236 |
| | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role | Q34389286 |
| | Chloroquine excretion following malaria prophylaxis | Q34420993 |
| | Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications | Q34583259 |
| | Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. | Q34660681 |
| | The history of lupus erythematosus. From Hippocrates to Osler | Q34684696 |
| | Chronic ulcerative stomatitis | Q34790917 |
| | Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery | Q35148912 |
| | Polymorphic light eruption | Q35200008 |
| | Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells | Q35268754 |
| | Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys | Q35324935 |
| | Antimicrobial therapies for Q fever | Q36169968 |
| | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence | Q36240425 |
| | Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells | Q36275163 |
| | Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review | Q36400444 |
| | Cardiomyopathy related to antimalarial therapy with illustrative case report | Q36521126 |
| | Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis | Q36753137 |
| | Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 |
| | Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century | Q36880738 |
| | Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus | Q37158591 |
| | Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice | Q37274730 |
| | The role of anti-malarials in rheumatoid arthritis--the American experience. | Q41109179 |
| | Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine | Q41152773 |
| | Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine | Q41168935 |
| | Systemic lupus erythematosus; a report on twelve cases treated with quinacrine (atabrine) and chloroquine (aralen). | Q41349197 |
| | Killing of Staphylococcus aureus in murine macrophages by chloroquine used alone and in combination with ciprofloxacin or azithromycin | Q41476422 |
| | Targeting autophagy in cancer | Q41912265 |
| | Chloroquine-induced cardiomyopathy-echocardiographic features | Q41912397 |
| | Chloroquine neuromyotoxicity. Clinical and pathologic perspective | Q41913997 |
| | Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes | Q41915280 |
| | Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. | Q41915692 |
| | Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. | Q41916874 |
| | Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis | Q41917273 |
| | Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study | Q41917416 |
| | Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study | Q41919048 |
| | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. | Q41919912 |
| | The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy | Q41920001 |
| | Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials | Q41921005 |
| | Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate | Q41921033 |
| | Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy | Q41921243 |
| | Treatment of classic Whipple's disease: from in vitro results to clinical outcome | Q41924598 |
| | Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine | Q41924708 |
| | Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. | Q41924789 |
| | Therapies for active rheumatoid arthritis after methotrexate failure | Q41925478 |
| | Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement | Q41925667 |
| | Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease | Q41926522 |
| | Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. | Q41927429 |
| | Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. | Q41929433 |
| | Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. | Q41929601 |
| | Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate | Q41931253 |
| | Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. | Q41932765 |
| | Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders | Q41932770 |
| | Alterations in the internucleosomal DNA helical twist in chromatin of human erythroleukemia cells in vivo influences the chromatin higher‐order folding | Q41933313 |
| | Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis | Q41934142 |
| | Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome | Q41934841 |
| | On the inhibitory effect of chloroquine on blood platelet aggregation | Q41935192 |
| | Use of antimalarials in dermatology | Q41935321 |
| | Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells | Q41935560 |
| | Hydroxychloroquine-induced myopathy | Q41936886 |
| | Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. | Q41937744 |
| | Effect of chloroquine on malignant lymphoreticular and pigmented cells in vitro | Q41938039 |
| | Nuclear magnetic resonance studies of the interaction of chloroquine diphosphate with adenosine 5'-phosphate and other nucleotides | Q41939051 |
| | Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study | Q41941663 |
| | New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases | Q41941843 |
| | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 |
| | Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? | Q41943988 |
| | The in-vitro and ex-vivo effects of chloroquine sulphate on platelet function: implications for malaria prophylaxis in patients with impaired haemostasis. | Q41944066 |
| | Chloroquine inhibits Paracoccidioides brasiliensis survival within human monocytes by limiting the availability of intracellular iron. | Q41945512 |
| | Hydroxychloroquine-induced restrictive cardiomyopathy | Q41945578 |
| | Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma | Q41945980 |
| | Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes | Q41946037 |
| | Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine | Q41946455 |
| | Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction | Q41946807 |
| | Ocular effects and safety of antimalarial agents | Q41947045 |
| | Treatment of chronic lupus erythematosus with atabrine and chloroquine | Q41947308 |
| | Chloroquine diphosphate in treatment of discoid lupus erythematosus | Q41947617 |
| | Atabrine and chloroquine in the treatment of chronic discoid lupus erythematosus. | Q41947620 |
| | Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). | Q42966712 |
| | CLIPPERS: Induction and maintenance of remission using hydroxychloroquine | Q43112108 |
| | Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells | Q43281341 |
| | Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro | Q44274859 |
| | Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. | Q44301752 |
| | Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus | Q45307599 |
| | Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis | Q45324656 |
| | Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. | Q46789109 |
| | Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. | Q47162451 |
| | Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome. | Q52234497 |
| | The history of antimalarials. | Q53622368 |
| | Whipple's Disease | Q55933942 |
| | Drugs for discoid lupus erythematosus | Q57692874 |
| | Mechanisms Involved in the Low‐Level Regeneration of CD4+Cells in HIV‐1–Infected Patients Receiving Highly Active Antiretroviral Therapy Who Have Prolonged Undetectable Plasma Viral Loads | Q61565774 |
| | Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis | Q62580283 |
| | Possible efficacy of hydroxychloroquine on accelerated nodulosis during methotrexate therapy for rheumatoid arthritis | Q70724673 |
| | Effect of low intraphagolysosomal pH on antimicrobial activity of antibiotics against ingested staphylococci | Q71800112 |
| | Experimental results on chloroquine and AIDS-related opportunistic infections | Q73594473 |
| | Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial | Q37289596 |
| | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 |
| | Ocular safety of hydroxychloroquine. | Q37519428 |
| | Thrombosis in systemic lupus erythematosus: risk and protection | Q37642828 |
| | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches | Q37658524 |
| | Chloroquine use improves dengue-related symptoms | Q37674854 |
| | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 |
| | Hydroxychloroquine: from malaria to autoimmunity | Q37827403 |
| | Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. | Q37829627 |
| | Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy | Q38179651 |
| | Hydroxychloroquine: a multifaceted treatment in lupus | Q38214068 |
| | Tropheryma whipplei and Whipple's disease | Q38216060 |
| | Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells | Q38282082 |
| | Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. | Q38283188 |
| | Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome | Q38297919 |
| | Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases | Q38360827 |
| | Antibiotic treatment and relapse in Whipple's disease. Long-term follow-up of 88 patients | Q38394341 |
| | Recent advances in the study of Q fever epidemiology, diagnosis and management | Q38445496 |
| | Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. | Q38530430 |
| | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases | Q38561490 |
| | Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents. | Q38569669 |
| | The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination | Q38637388 |
| | Complications of antimalarial therapy | Q38668320 |
| | Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies | Q38674653 |
| | Research progress of hydroxychloroquine and autophagy inhibitors on cancer. | Q39021076 |
| | Hydroxychloroquine in systemic lupus erythematosus (SLE). | Q39031764 |
| | Chloroquine engages the immune system to eradicate irradiated breast tumors in mice | Q39076936 |
| | Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases | Q39360987 |
| | Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer | Q39649021 |
| | Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells | Q39807701 |
| | Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis | Q39887289 |
| | Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. | Q39904465 |
| | Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study | Q40086492 |
| | Coxiella burnetii infection of aortic aneurysms or vascular grafts: report of 30 new cases and evaluation of outcome | Q40444558 |
| | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. | Q40474976 |
| | Fungistatic effect of hydroxychloroquine, lessons from a case | Q40515410 |
| | Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study | Q40524514 |
| | Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Q40568140 |
| | Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum | Q40968248 |
| P433 | issue | 8 | |
| P921 | main subject | hydroxychloroquine | Q421094 |
| | chloroquine | Q422438 |
| P304 | page(s) | 653-671 | |
| P577 | publication date | 2018-08-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review | |
| P478 | volume | 38 | |